Search > Vasculitis
446 Participants NeededMy employer runs this trial

FT839 for Autoimmune Diseases

FC
NS
Overseen ByNatalie Shiff, MD
Age: 18+
Sex: Any
Trial Phase: Phase 1 & 2
Sponsor: Fate Therapeutics
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

The primary objectives of this trial are to evaluate the safety and tolerability and to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose of FT839 with or without rituximab and/or background therapy and/or conditioning therapy.

Are You a Good Fit for This Trial?

This trial is for adults diagnosed with autoimmune diseases like lupus, scleroderma-related lung disease, dermatomyositis, polymyositis, vasculitis, rheumatoid arthritis, or osteoarthritis. Participants must meet specific health requirements set by the study team.

Inclusion Criteria

My moderate to severe disease did not improve after at least two treatments.
Able to provide informed consent and comply with study procedures
I am between 18 and 70 years old.
See 2 more

Exclusion Criteria

I have received anti-CD19 or anti-CD20 therapy in the past 6 months.
Known allergies to study treatments
I have received CAR T-cell therapy or had an organ transplant.
See 7 more

What Are the Treatments Tested in This Trial?

Interventions

  • FT839

Trial Overview

The study is testing a new drug called FT839 alone or combined with rituximab and/or other standard treatments to find the safest dose and see how well people tolerate it.

How Is the Trial Designed?

8

Treatment groups

Experimental Treatment

Group I: FT839 with stable background therapy (Regimen D)Experimental Treatment1 Intervention
Group II: FT839 monotherapy (Regimen C)Experimental Treatment1 Intervention
Group III: FT839 + Rituximab with stable background therapy (Regimen B)Experimental Treatment1 Intervention
Group IV: FT839 + Rituximab (Regimen A)Experimental Treatment1 Intervention
Group V: Conditioning + FT839 with stable background therapy (Regimen H)Experimental Treatment1 Intervention
Group VI: Conditioning + FT839 + Rituximab with stable background therapy (Regimen F)Experimental Treatment1 Intervention
Group VII: Conditioning + FT839 + Rituximab (Regimen E)Experimental Treatment1 Intervention
Group VIII: Conditioning + FT839 (Regimen G)Experimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Fate Therapeutics

Lead Sponsor

Trials
22
Recruited
1,200+

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.